QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
Phase 1 study to assess the safety, preliminary efficacy of PD-L1 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose in subjects with locally advanced or metastatic solid cancers.
Locally Advanced Solid Tumor|Metastatic Cancer|Solid Tumor
BIOLOGICAL: PD-L1 t-haNK
MTD or HTD and RP2D., Maximum tolerated dose or highest tested dose and recommended phase 2 dose., 1 year|Incidence of DLTs and treatment-emergent adverse events, Incidence of DLTs and treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0., 1 year
Objective Response Rate (ORR), ORR in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 and modified RECIST guidelines for immunotherapy trials (iRECIST)., 1 year|Progression-free Survival (PFS), Progression-free Survival (PFS) by RECIST Version 1.1 and iRECIST., 1 year|Overall Survival (OS), 1 year
Phase 1 study to assess the safety, preliminary efficacy of PD-L1 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose for subjects with locally advanced or metastatic solid cancers. The study will be conducted in 2 parts: part 1 will involve dose escalation and part 2 will involve expansion of the recommended phase 2 dose.